• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Solid drug nanoparticles could improve delivery of HIV therapies

October 21, 2016 By Sarah Faulkner

Solid drug nanoparticles could improve delivery of HIV therapiesResearchers from the University of Liverpool have developed a method of delivering pediatric HIV drugs using solid drug nanoparticles, according to a study published today in Nature Communications. 

There are no clinically available oral nanotherapies for HIV patients and pediatric HIV medicines are not widely available, according to the researchers.

The team examined a current pediatric HIV medicine that uses ethanol to solubilize lopinavir, an antiretroviral. The drug is not easily soluble, so creating an oral formulation that can efficiently deliver the drug for treatment is tricky.

Study researchers generated a water dispersible nanotherapy using solid drug nanoparticles, removing the need to use alcohol in the medicine. Solid drug nanoparticles can improve drug absorption in the body, which reduces the dose and cost per dose. The researchers reported their method for screening for possible solid drug nanoparticle candidates with high drug loading capacity.

The nanoparticle’s preclinical development process is detailed in the team’s published study and the nanoparticles are being used in ongoing human trials.

“The fruits of our interdisciplinary research are beginning to be realized,” pharmacology professor Andrew Owen said in prepared remarks. “Our approach has the potential to overcome challenges with current antiretroviral therapy, which include administration of high doses needed to achieve efficacious concentrations in the body, and the urgent need for better formulations for children living with HIV.”

“The wide applicability of our strategy has implications for multiple therapy development programs and we are actively engaged in the creation of nanomedicine options to impact a range of clinical needs,” materials chemistry professor Steve Rannard added.

Filed Under: Featured, Nanoparticles, Research & Development Tagged With: University of Liverpool

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS